Vanguard Group Inc. increased its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 9.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,665,758 shares of the medical research company’s stock after buying an additional 139,901 shares during the period. Vanguard Group Inc. owned approximately 3.60% of Enzo Biochem worth $13,943,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Millrace Asset Group Inc. bought a new position in shares of Enzo Biochem during the first quarter valued at about $1,256,000. Wells Fargo & Company MN increased its position in shares of Enzo Biochem by 47.9% in the first quarter. Wells Fargo & Company MN now owns 312,813 shares of the medical research company’s stock valued at $2,618,000 after buying an additional 101,264 shares during the period. TIAA CREF Investment Management LLC increased its position in shares of Enzo Biochem by 17.9% in the first quarter. TIAA CREF Investment Management LLC now owns 371,069 shares of the medical research company’s stock valued at $3,106,000 after buying an additional 56,301 shares during the period. Teachers Advisors LLC increased its position in shares of Enzo Biochem by 60.7% in the fourth quarter. Teachers Advisors LLC now owns 112,023 shares of the medical research company’s stock valued at $777,000 after buying an additional 42,302 shares during the period. Finally, State Street Corp increased its position in shares of Enzo Biochem by 7.3% in the fourth quarter. State Street Corp now owns 567,070 shares of the medical research company’s stock valued at $3,931,000 after buying an additional 38,672 shares during the period. Institutional investors own 62.85% of the company’s stock.

Enzo Biochem, Inc. (NYSE:ENZ) traded up 0.82% during mid-day trading on Monday, reaching $11.10. The company had a trading volume of 19,017 shares. The firm has a market capitalization of $515.12 million, a price-to-earnings ratio of 15.57 and a beta of 0.97. Enzo Biochem, Inc. has a 12-month low of $4.88 and a 12-month high of $12.04. The firm has a 50-day moving average price of $11.21 and a 200 day moving average price of $9.25.

ILLEGAL ACTIVITY WARNING: “Enzo Biochem, Inc. (ENZ) Shares Bought by Vanguard Group Inc.” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://theolympiareport.com/2017/08/28/enzo-biochem-inc-enz-shares-bought-by-vanguard-group-inc.html.

Several research analysts have recently issued reports on ENZ shares. Zacks Investment Research downgraded shares of Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. BidaskClub upgraded Enzo Biochem from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.